Rheumatoid Arthritis and Pregnancy in Obstetric Practice
Rheumatoid arthritis (RA) during pregnancy is associated with maternal risk related to disease activity and medication exposures. (assets.contentstack.io) A coordinated plan addressing disease control, preconception medication management, and trimester-specific therapy selection is recommended across rheumatology and obstetrics/gynecology. (assets.contentstack.io)
Estimated 15-Minute Presentation Outline for Gynecologists
- 0:00–2:30 RA in pregnancy: expected clinical course, flare risks, and obstetric implications. (assets.contentstack.io)
- 2:30–6:30 Preconception assessment and counseling: medication safety review, disease control goals, and comanagement steps. (assets.contentstack.io)
- 6:30–10:30 Pregnancy medication strategy: pregnancy-compatible DMARDs and trimester-specific biologic adjustments. (assets.contentstack.io)
- 10:30–12:30 Labor, neonatal planning, and infectious considerations tied to in utero biologic exposure. (assets.contentstack.io)
- 12:30–15:00 Postpartum and lactation: RA flare prevention and lactation-compatible therapies. (assets.contentstack.io)
Maternal Disease Course and Obstetric Implications
Disease control before conception is prioritized because uncontrolled systemic inflammation is associated with poor pregnancy outcomes. (assets.contentstack.io) Disease flares may occur postpartum, requiring proactive medication planning for the postpartum period. (assets.contentstack.io) Medication selection requires balancing fetal exposure risk with the risk of maternal disease activity. (assets.contentstack.io)
Preconception Assessment and Counseling Workflow
Medication reconciliation is recommended before conception to identify therapies that are compatible with pregnancy or lactation. (assets.contentstack.io) Preconception counseling is recommended when conception is considered during periods of disease quiescence and while receiving pregnancy-compatible medications. (assets.contentstack.io) Collaborative care planning with obstetrics/gynecology and rheumatology is recommended for contraception, pregnancy assessment and management, and medication use. (assets.contentstack.io) Clinical discussions should be initiated with sufficient time to permit medication changes and demonstration of tolerability and disease stability, generally several months. (assets.contentstack.io)
Medication Selection Algorithm for Pregnancy
Pregnancy-compatible conventional DMARDs
- Hydroxychloroquine is strongly recommended preconception and during pregnancy. (assets.contentstack.io)
- Sulfasalazine is strongly recommended preconception and during pregnancy. (assets.contentstack.io)
- Colchicine is strongly recommended preconception and during pregnancy. (assets.contentstack.io)
- Azathioprine and 6-mercaptopurine are strongly recommended preconception and during pregnancy, and compatible with breastfeeding. (assets.contentstack.io)
Corticosteroids and symptomatic control
- Prednisone is conditionally recommended preconception and during pregnancy, with tapering to <20 mg/day via addition of pregnancy-compatible immunosuppressants when needed. (assets.contentstack.io)
- Nonsteroidal anti-inflammatory drugs are conditionally recommended preconception and used with trimester restrictions, with discontinuation in the third trimester when indicated. (assets.contentstack.io)
Pregnancy-compatible biologics
- Certolizumab is strongly recommended preconception, during pregnancy, and compatible with breastfeeding. (assets.contentstack.io)
- TNF inhibitors with IgG1 Fc constructs (infliximab, etanercept, adalimumab, golimumab) are considered compatible with pregnancy, with discontinuation in the third trimester several half-lives prior to delivery when disease control permits. (assets.contentstack.io)
- Rituximab is recommended as compatible in specific clinical contexts, with discontinuation at conception and consideration during pregnancy for life- or organ-threatening disease. (assets.contentstack.io)
- Non–TNF inhibitor IgG-based biologics with limited safety data are conditionally recommended only in the periconception period and are recommended to be discontinued during pregnancy at the first positive pregnancy test. (assets.contentstack.io)
Key High-Risk Medication Discontinuation Rules
- Methotrexate is strongly recommended against use during pregnancy. (assets.contentstack.io)
- Methotrexate should be stopped 1–3 months prior to conception, and folic acid 5 mg/day should be provided when pregnancy is anticipated or confirmed. (assets.contentstack.io)
- Leflunomide is strongly recommended against use during pregnancy, with cholestyramine washout recommended for detectable metabolite levels. (assets.contentstack.io)
- Mycophenolate mofetil and mycophenolic acid are strongly recommended against use during pregnancy, with discontinuation >6 weeks prior to conception to assess disease stability. (assets.contentstack.io)
- Known teratogens (methotrexate, mycophenolate, cyclophosphamide, thalidomide) require discontinuation within 3 months prior to conception. (assets.contentstack.io)
Treatment Initiation Thresholds and Disease Control Targets
No specific RA treatment initiation blood pressure thresholds apply. (assets.contentstack.io) Disease quiescence and stability on pregnancy-compatible medication are prioritized for conception planning. (assets.contentstack.io)
Common Pitfalls to Avoid in Obstetric Care of RA
Medication changes without adequate preconception planning are discouraged because medication timing and disease stability monitoring require several months in typical clinical workflows. (assets.contentstack.io) Continuation of strongly teratogenic agents in pregnancy is contraindicated in guideline-based medication planning. (assets.contentstack.io) Late-pregnancy dosing of IgG1 TNF inhibitors may increase neonatal exposure with potentially higher neonatal serum drug levels, which supports guideline-based third-trimester discontinuation planning when disease control permits. (assets.contentstack.io)
Targeted Management by Pregnancy Stage
Periconception and first trimester
- Certolizumab is strongly recommended to continue through conception and during pregnancy. (assets.contentstack.io)
- TNF inhibitors with IgG1 Fc constructs are compatible with pregnancy, with continuation acceptable through early pregnancy. (assets.contentstack.io)
- Non–TNF inhibitor IgG-based biologics are conditionally compatible in the periconception period but are recommended to stop at the first positive pregnancy test. (assets.contentstack.io)
Third trimester and delivery planning
- For TNF inhibitors with IgG1 Fc constructs, discontinuation in the third trimester several half-lives prior to delivery is recommended when disease control is adequate. (assets.contentstack.io)
- Continuation of TNF inhibitors through delivery may be considered when maternal disease activity is active, with recognition of significant neonatal drug levels. (assets.contentstack.io)
Lactation-Compatible Therapy and Postpartum Planning
- Hydroxychloroquine, colchicine, sulfasalazine, rituximab, and all TNF inhibitors are strongly recommended as compatible with breastfeeding. (assets.contentstack.io)
- Prednisone is recommended as compatible with breastfeeding at doses <20 mg/day, with guidance to delay breastfeeding or discard milk for higher doses taken close to feeds. (assets.contentstack.io)
- Glucocorticoid dose thresholds support postpartum feeding logistics to reduce infant exposure. (assets.contentstack.io)
Maternal–Fetal Collaboration Considerations for Gynecology
Immunomodulating therapy planning should be incorporated into routine obstetric care pathways with attention to trimester-specific exposure risks. (assets.contentstack.io) A multidisciplinary approach supports safe and effective pregnancy outcomes by aligning maternal disease control with fetal and neonatal risk mitigation. (assets.contentstack.io)